Response to correspondence about our article Hernández-Cruz B, Otero-Varela L, Freire-González M, Busquets-Pérez N, García González AJ, Moreno-Ramos M, et al. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry. Ann Rheum Dis. 2024 Aug 27;83(9):1189-99. doi:10.1136/ard-2023-225271.

IF 20.6 1区医学 Q1 RHEUMATOLOGY

Annals of the Rheumatic Diseases Pub Date : 2025-09-30 DOI:10.1016/j.ard.2025.08.022

Blanca Hernández-Cruz

引用次数: 0

对文章回复Hernández-Cruz B， Otero-Varela L, Freire-González M, busquets - p雷斯N， García González AJ, Moreno-Ramos M，等。来自BIOBADASER注册的真实世界数据显示，Janus激酶抑制剂和肿瘤坏死因子抑制剂在类风湿关节炎、银屑病关节炎和脊椎关节炎中显示出良好的安全性和相似的持久性。[j] .中国医学杂志。2024年8月27日；31(9):1189-99。doi: 10.1136 / ard - 2023 - 225271。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of the Rheumatic Diseases 医学-风湿病学

CiteScore

35.00

自引率

9.90%

发文量

3728

审稿时长

1.4 months

期刊介绍： Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.